SEC Form 5 · accession 0001209191-19-004733
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Troy Edward Wilson
Officer — President and CEO · Director
Period of report
Dec 31, 2018
Accepted (ET)
Jan 22, 2019 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 16, 2018 | G | 32,985 | $0.00 | D | 26,041 | D | |
| Common Stock | Nov 16, 2018 | G | 32,985 | $0.00 | A | 1,768,976 | I | by Red Fish Blue Fish Revocable Trust |
| Common Stock | holding | — | — | — | 406,736 | I | by Araxes Pharma LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the purchase or sale of securities.